Trial Number

209-21

Condition

Lung Cancer

Participant Age Range

22 years and older

Participant Gender

Any

Enrolling Participants

Yes

Overview

EF-36/Keynote B36: A Pilot, Single Arm, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Intrathoracic Non-small Cell Lung Cancer

This is a multicenter, single arm, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System concomitant with IV pembrolizumab (also known as MK-3475) in subjects previously untreated for their advance or metastatic intrathoracic, PD-L1 positive (TPS=1% [tumor proportion score]) non-small cell lung cancer (NSCLC).

Provider

Related Clinical Trials

Click on the category you are interested in.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
Are you a current MemorialCare patient?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.